Introduction
============

Electronic Health Record (EHR) systems are becoming highly prevalent today and have the potential [@b1-amia_cri_2013_098] to add to the success of spontaneous reporting systems for post marketing surveillance of drugs, especially to identify risky drug interactions. Although most EHR based drug safety research relies on coded information, studies have established several advantages to using the clinical text. In this work, we apply data mining methods on the textual portion of EHRs to *learn* drug-drug interaction (DDI) signals, which, to our knowledge is the first study of its kind.

Methods
=======

We use an ontology-based text processing workflow to tag a corpus of 9,078,736 time-stamped textual notes from the Stanford Hospital (STRIDE) with drug and disease concepts (1,164 drugs and 14 events) and create a concept timeline for each patient. We check for a *drug-drug-event* interaction signal, by comparing the odds of the event among patients on both drugs to that in patients on at most one of the drugs. We adjust the odds ratio for confounding by age, gender, race, drug count, disease count and note count. Finally, we build a gold standard of 560 known interactions and an equal number of random unknown interactions and use it to validate our method.

Results
=======

Our method achieves an area under the Receiver Operator Characteristic curve of 81.5% on the gold standard, with a sensitivity of 37.98% at a specificity of 96.56% and a positive predictive value of 91.71%. We also calculate the prevalence of the event among patients on drug combinations representing true interactions ( [Table 1](#t1-amia_cri_2013_098){ref-type="table"} ), and argue that such prevalence information can be a unique resource to prioritize known interactions.

Discussion
==========

Our work shows the feasibility of the use of EHR text to generate hypotheses about DDIs and to examine their real world prevalence, which could serve as an important step forward for Phase IV drug surveillance and meaningful use of EHRs. Having longitudinal coverage and being minimally affected by reporting and publicity bias, makes the prevalence information generated from EHRs extremely useful for Computerized Physician Order Entry (CPOE) systems to tackle the problem of alert fatigue; and in choosing combination therapy from among many drug combinations. Confounding, accuracy of concept recognition, detection of the drug interaction period and other limitations of this method will be addressed in future work.

Table
=====

###### 

The drug combinations with the highest event prevalence in STRIDE, for each event. (Prev = \#(Exposed and affected)/\#(Exposed))

  *Adverse Event (\#Patients)*   *Drug1*               *Drug2*          *a*    *b*    *Prev. (%)*
  ------------------------------ --------------------- ---------------- ------ ------ -------------
  Parkinsonian Symptoms (3541)   levodopa              lorazepam        176    235    42.82
  Cardiac Arrhythmias (88555)    potassium chloride    lisinopril       1091   1615   40.32
  Neutropenia (14322)            paclitaxel            trastuzumab      140    567    19.8
  Bradycardia (22906)            amiodarone            metoprolol       796    3671   17.82
  Hypoglycemia (11150)           glipizide             lisinopril       367    2160   14.52
  Acute Renal Failure (32197)    hydrochlorothiazide   ibuprofen        884    8375   9.55
  Hyperkalemia (4973)            potassium chloride    spironolactone   349    3471   9.14
  Hyperglycemia (19189)          prednisone            salmeterol       379    4612   7.59
  Nephrotoxicity (1460)          fluconazole           tacrolimus       85     1208   6.57
  Pancytopenia (8718)            mercaptopurine        azathioprine     15     278    5.12
  Hypokalemia (8405)             prednisone            salmeterol       222    4982   4.27
  Serotonin Syndrome (674)       tramadol              duloxetine       57     1301   4.2
  QT prolongation (1260)         amiodarone            ciprofloxacin    46     2487   1.82
  Rhabdomyolysis (1378)          ciprofloxacin         simvastatin      50     5184   0.96
